Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

Summary

The main purpose of the study was to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS) particpants treated with Mavenclad® for 2 years (24 months).

Timeline

Start

2018-06-20

Primary completion

2021-11-12

Completion

2021-11-12

Publications

• Brochet B, Langdon D, Havrdova EK, Lechner-Scott J, Montalban X, Patti F, Piehl F, Solari A, Hupperts R, Alexandri N, Lehn A, Smyk A, Selmaj K; CLARIFY-MS Investigators. Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study. Neurol Ther. 2026 Mar 10. doi: 10.1007/s40120-026-00897-0. Online ahead of print.
• Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maida EM, Alexandri N, Smyk A, Nolting A, Keller B, Montalban X, Kubala Havrdova E. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Mult Scler. 2023 Dec;29(14):1808-1818. doi: 10.1177/13524585231205962. Epub 2023 Nov 18.

Drugs

Indications